 |
TREATMENTS IN THE PIPELINE: 150 headlines |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||
| Our 670 MySpace Friends The New Face of MS |
||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||||||||||||||||||
| July 2006 | ||||||||||||||||||||||||||||||||||||||
| August 2006 | ||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||
Thursday
Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model
"Xanthus Pharmaceuticals Inc., a privately-held drug development company, today presented data that Symadex(TM) reverses the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis (MS). The presentation was made by Stephen J. Karlik, PhD, Professor of Diagnostic Radiology at the University of Western Ontario, London, Ontario, together with researchers from Xanthus in aposter session at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Madrid, Spain.
Dr. Karlik used a model of experimental allergic encephalomyelitis(EAE) for the study. This same model was used by Dr. Karlik and his colleagues for published studies with natalizumab and related molecules. The study demonstrated that Symadex can reverse the clinical and pathological signs of chronic disease and that it can permit nerve remyelination. In addition, longer dosing resulted in continued benefit and the pathological changes including inflammation and vascular abnormalities were reversed. Importantly, Symadex did not affect circulating immune cell numbers, suggesting that it is not a general immunosuppressive agent....MORE
"Xanthus Pharmaceuticals Inc., a privately-held drug development company, today presented data that Symadex(TM) reverses the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis (MS). The presentation was made by Stephen J. Karlik, PhD, Professor of Diagnostic Radiology at the University of Western Ontario, London, Ontario, together with researchers from Xanthus in aposter session at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Madrid, Spain.
Dr. Karlik used a model of experimental allergic encephalomyelitis(EAE) for the study. This same model was used by Dr. Karlik and his colleagues for published studies with natalizumab and related molecules. The study demonstrated that Symadex can reverse the clinical and pathological signs of chronic disease and that it can permit nerve remyelination. In addition, longer dosing resulted in continued benefit and the pathological changes including inflammation and vascular abnormalities were reversed. Importantly, Symadex did not affect circulating immune cell numbers, suggesting that it is not a general immunosuppressive agent....MORE